Company Lipocine Inc.

Equities

LPCN

US53630X2036

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.798 ^USD	+5.44%		-8.96%	+71.96%

Apr. 12	Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial	MT
Apr. 11	Top Premarket Gainers	MT

Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Number of employees: 17

USD in Million	2022	Weight	2023	Weight	Delta
Oral Delivery Solutions 100.0 %	1	100.0 %	-3	100.0 %	-670.16%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	1	100.0 %	-3	100.0 %	-670.16%

Managers	Title	Age	Since
Mahesh Patel CEO	Chief Executive Officer	67	96-12-31
Anthony DelConte CTO	Chief Tech/Sci/R&D Officer	66	-
Krista Fogarty AUD	Comptroller/Controller/Auditor	56	18-09-30
Nachiappan Chidambaram PRN	Corporate Officer/Principal	55	14-06-30

Members of the board	Title	Age	Since
Richard Dana Ono BRD	Director/Board Member	71	14-01-05
Mahesh Patel CEO	Chief Executive Officer	67	96-12-31
John W. Higuchi BRD	Director/Board Member	56	12-12-31
Jeffrey Arvin Fink BRD	Director/Board Member	66	14-01-05
Jill M. Jene BRD	Director/Board Member	51	22-04-10
Spyridon Papapetropoulos CHM	Chairman	52	22-03-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	5,316,166	5,160,433 ( 97.07 %)	336 ( 0.006320 %)	97.07 %

Name	Equities	%	Valuation
Vanguard Global Advisers LLC 4.166 %	221,459	4.166 %	1 M $
Mahesh Patel 2.113 %	112,311	2.113 %	584 017 $
BlackRock Institutional Trust Co. NA 1.408 %	74,846	1.408 %	389 199 $
Susquehanna Securities LLC 1.065 %	56,601	1.065 %	294 325 $
Geode Capital Management LLC 0.9190 %	48,854	0.9190 %	254 041 $
John W. Higuchi 0.7675 %	40,797	0.7675 %	212 144 $
Two Sigma Advisers LP 0.4933 %	26,222	0.4933 %	136 354 $
Renaissance Technologies LLC 0.3536 %	18,797	0.3536 %	97 744 $
STATE STREET CORPORATION 0.3504 %	18,626	0.3504 %	96 855 $
NFS Netfonds Financial Service GmbH 0.0774 %	4,117	0.0774 %	21 408 $

Lipocine, Inc.

675 Arapeen Drive Suite 202

84108, Salt Lake City

+801 994 7383

http://www.lipocine.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.798 USD

Average target price

33 USD

Spread / Average Target

+587.83%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
LIPOCINE INC.	+71.96%	25.5M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs